The rules governing how drugs get assessed, priced, and accessed are being rewritten simultaneously. We help biotech and pharma leadership navigate what's coming — before it becomes a crisis.
JCA has changed when EU access strategy must begin. MFN is linking US prices to European HTA outcomes. Cost-effectiveness thresholds are being reset by trade negotiations, not health economics. Most access teams are treating these as separate problems. They're not.
Short-burn, high-impact work designed for the moments when the standard playbook doesn't apply and the stakes are high. Scope, duration, and fees are tailored to the complexity of each situation — initial engagements typically start from 1–2 weeks.
Rapid assessment of EU access viability, pricing corridor, HTA risks, and launch sequencing — designed for asset partnering and out-licensing readiness. Payer credibility drives asset valuation.
Translate complex, early, or imperfect evidence into a credible payer narrative. Identify where your evidence package holds under EU HTA scrutiny — and where it doesn't. Build a strategy to close the gap.
Scenario modelling under EU HTA, IRP, and MFN pressure. Understand the pricing implications of the current policy environment and build a sequencing strategy that holds across scenarios.
Most access strategies don't fail on design. They fail when evidence, policy, and commercial expectations diverge — and no one has mapped the gap clearly enough to act.
"Most access strategies don't fail on design — they fail when evidence, policy and commercial expectations diverge. I help teams navigate that gap."
Latif Strategic Advisory is an independent consultancy providing strategic advisory on market access, pricing, evidence strategy, and policy for biotech and pharma leadership.
Founded by Faisal Latif, who brings a combination of in-house operator experience and senior advisory practice. At Bristol Myers Squibb, Faisal led HEOR for BMS's flagship thoracic oncology portfolio at the UK affiliate — directing evidence strategy and team budget, and delivering NICE reimbursement for BMS's breakthrough indication in first-line lung cancer — before moving into global access and pricing, leading Value, Access & Pricing strategy across ex-US Major Markets and ultimately heading the EU Cluster VAP organisation. At IQVIA, as Senior Principal in Value & Access within the EMEA Life Sciences Strategy practice, he led advisory mandates for global and regional pharma leadership teams covering pricing, market access, and evidence strategy across some of the most commercially consequential launches in European pharma.
LSA works with leadership teams at the point where access strategy becomes a live commercial problem — when evidence is still evolving, policy is shifting, and the gap between what's planned and what's achievable is starting to show.
Founder
Latif Strategic Advisory
Senior Principal · Value & Access, EMEA Life Sciences Strategy
IQVIA
Head, EU Cluster · Value, Access & Pricing
Bristol Myers Squibb
HEOR Lead, Thoracic Oncology · UK Affiliate
Bristol Myers Squibb
Focus areas
EU HTA (JCA) · Pricing strategy · MFN/IRP · Early access planning · Oncology
Commentary at the intersection of EU HTA, global pricing, and policy — for biotech leadership navigating a rapidly shifting environment.
The contradiction at the heart of Most Favored Nation pricing — and what it means for the credibility of HTA as a neutral process.
Pricing · MFNThe first threshold change since NICE was founded in 1999 — announced alongside a trade deal. The technical clothing remains. The emperor underneath has changed.
MFN · Market AccessWith GLOBE taking effect October 1, the decisions being made in the vacuum of leadership silence are still decisions. They're just being made by default instead of by design.
If your access strategy is facing a moment of complexity — early data, shifting policy, a partnership or launch decision — get in touch.